IMpower132: Atezolizumab plus platinum‐based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients

IMpower132 explored the safety and efficacy of atezolizumab plus pemetrexed and platinum‐based chemotherapy as first‐line treatment for advanced non‐small‐cell lung cancer (NSCLC). Key eligibility criteria for the phase 3, open‐label, IMpower132 study included age ≥18 y, histologically or cytologica...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Sci
Autori principali: Nishio, Makoto, Saito, Haruhiro, Goto, Koichi, Watanabe, Satoshi, Sueoka‐Aragane, Naoko, Okuma, Yusuke, Kasahara, Kazuo, Chikamori, Kenichi, Nakagawa, Yuki, Kawakami, Tomohisa
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2021
Soggetti:
ORIGINAL ARTICLES
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8019191/
https://ncbi.nlm.nih.gov/pubmed/33462883
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14817
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi